Jennison Associates LLC Increases Stock Holdings in argenx SE (NASDAQ:ARGX)

Jennison Associates LLC boosted its position in argenx SE (NASDAQ:ARGX) by 27.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 302,149 shares of the company’s stock after purchasing an additional 64,183 shares during the quarter. Jennison Associates LLC owned about 0.50% of argenx worth $185,821,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Cromwell Holdings LLC boosted its holdings in shares of argenx by 73.3% in the 3rd quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock valued at $85,000 after purchasing an additional 66 shares during the last quarter. GAMMA Investing LLC raised its position in argenx by 47.5% in the third quarter. GAMMA Investing LLC now owns 174 shares of the company’s stock valued at $94,000 after purchasing an additional 56 shares during the period. Blue Trust Inc. boosted its holdings in argenx by 413.9% in the 3rd quarter. Blue Trust Inc. now owns 370 shares of the company’s stock worth $201,000 after acquiring an additional 298 shares during the period. Keudell Morrison Wealth Management purchased a new stake in shares of argenx during the third quarter valued at approximately $207,000. Finally, SG Americas Securities LLC boosted its stake in shares of argenx by 6.2% in the fourth quarter. SG Americas Securities LLC now owns 358 shares of the company’s stock valued at $220,000 after purchasing an additional 21 shares during the period. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenx Stock Performance

Shares of ARGX opened at $655.13 on Monday. argenx SE has a 12 month low of $349.86 and a 12 month high of $678.21. The stock has a fifty day moving average price of $632.58 and a 200 day moving average price of $571.05.

argenx (NASDAQ:ARGX) last announced its quarterly earnings results on Thursday, October 31st. The company reported $1.39 EPS for the quarter, beating the consensus estimate of $0.10 by $1.29. The company had revenue of $588.88 million for the quarter, compared to analyst estimates of $543.29 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. During the same quarter last year, the business earned ($1.25) earnings per share. On average, equities analysts forecast that argenx SE will post 2.78 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have commented on ARGX shares. HC Wainwright reiterated a “buy” rating and issued a $717.00 price objective (up previously from $670.00) on shares of argenx in a report on Tuesday, January 14th. William Blair raised argenx from a “market perform” rating to an “outperform” rating in a research report on Friday, November 1st. Wolfe Research raised argenx from a “peer perform” rating to an “outperform” rating and set a $697.00 price target for the company in a report on Tuesday, November 12th. Piper Sandler lifted their price objective on argenx from $620.00 to $725.00 and gave the stock an “overweight” rating in a report on Tuesday, January 7th. Finally, Guggenheim increased their target price on argenx from $585.00 to $665.00 and gave the company a “buy” rating in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $658.39.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.